Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial

Date
2017
Author
Reina Gutierez, Lourdes
Tuzun, Hasan
Sabovic, Miso
Subwongcharoen, Somboom
Maggioli, Arnaud
Carpentier, Patrick
van Bellen, Bonno
Karetova, Debora
Hanafiah, Harunarashid
Enriquez-Vega, Elizabeth
Kirienko, Alexander
Dzupina, Andrej
Metadata
Show full item record
Abstract
BACKGROUND: Chronic venous disorders (CVD) is estimated to affect 30% to 50% of women and 10% to 30% of men. The most widely prescribed treatment for CVD worldwide is micronized purified flavonoid fraction 500 mg (MPFF). The aim of this clinical trial was to develop a new once daily 1000-mg oral suspension of MPFF.
URI
http://hdl.handle.net/20.500.12627/116072
https://doi.org/10.23736/s0392-9590.17.03801-9
Collections